0001209191-23-057239.txt : 20231204 0001209191-23-057239.hdr.sgml : 20231204 20231204165441 ACCESSION NUMBER: 0001209191-23-057239 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231130 FILED AS OF DATE: 20231204 DATE AS OF CHANGE: 20231204 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rothera Mark CENTRAL INDEX KEY: 0001550424 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-51531 FILM NUMBER: 231464011 MAIL ADDRESS: STREET 1: C/O AEGERION PHARMACEUTICALS, INC. STREET 2: 101 MAIN STREET, SUITE 1850 CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Viracta Therapeutics, Inc. CENTRAL INDEX KEY: 0001061027 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943295878 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2533 S COAST HWY 101 STREET 2: SUITE 210 CITY: CARDIFF STATE: CA ZIP: 92007 BUSINESS PHONE: 858-400-8470 MAIL ADDRESS: STREET 1: 2533 S COAST HWY 101 STREET 2: SUITE 210 CITY: CARDIFF STATE: CA ZIP: 92007 FORMER COMPANY: FORMER CONFORMED NAME: MOSAIC PHARMACEUTICALS INC DATE OF NAME CHANGE: 19980709 FORMER COMPANY: FORMER CONFORMED NAME: SUNESIS PHARMACEUTICALS INC DATE OF NAME CHANGE: 19980501 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-11-30 0 0001061027 Viracta Therapeutics, Inc. VIRX 0001550424 Rothera Mark C/O VIRACTA THERAPEUTICS, INC. 2533 S COAST HWY 101, SUITE 210 CARDIFF CA 92007 1 1 0 0 President and CEO 0 Common Stock 2023-11-30 4 P 0 52094 0.494 A 52094 D Common Stock 2023-12-01 4 P 0 47906 0.4932 A 100000 D Represents the weighted average share price of an aggregate total of 52,094 shares purchased in the price range of $0.48 to $0.51 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Represents the weighted average share price of an aggregate total of 47,906 shares purchased in the price range of $0.4750 to $0.5130 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Daniel Chevallard, as Attorney-in-Fact 2023-12-04